艾司氯胺酮治疗成人抑郁:PRISMA系统综述与Meta分析
该系统综述与Meta分析检索MEDLINE(2024年3月24日,关键词「esketamine」),纳入87篇文章,评估鼻内艾司氯胺酮对抑郁与自杀意念的疗效及副作用。结果显示第2-4周抑郁效应量弱但显著(0.15-0.23),自杀意念效应在任何时间点均不显著;作者认为其作为抗抑郁药增效治疗难治性抑郁的疗效 modest,且对自杀意念本身无效。
要点
- 第2-4周抑郁效应量弱但显著(0.15-0.23),与不典型抗精神病药增效策略相似。
- 自杀意念效应量在任何时间点均不显著,敏感性分析结果一致。
- 需结合艾司氯胺酮滥用潜力及长期效应尚不完全清楚来考量上述发现。
核心结论
- 研究结果表明,艾司氯胺酮作为抗抑郁药增效治疗对难治性抑郁的疗效 modest(与不典型抗精神病药增效策略相似),且对自杀意念本身无效。
- 这些发现需结合艾司氯胺酮的滥用潜力及长期效应仍不完全清楚来考量。
- 文中讨论了测试阶段关于死亡和新发自杀意念的一些警示信号及其他监管问题。
研究设计与样本
- 采用PRISMA方法系统检索MEDLINE,关键词为「esketamine」,检索日期为2024年3月24日。
- 数据处理与统计分析使用R 4.3.3版本,Meta分析使用METAFOR包。
- 初步识别1115篇文章,最终纳入87篇进行分析与讨论。
主要发现
- 第2-4周随机对照试验多为阴性或失败,但Meta分析显示抑郁有弱但显著的阳性效应(第2-4周效应量范围0.15-0.23)。
- 该抑郁效应与不典型抗精神病药增效治疗难治性抑郁的策略相似。
- 自杀意念的效应量在任何时间点均不显著。
- 敏感性分析产生相同结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需结合艾司氯胺酮的滥用潜力及长期效应仍不完全清楚来考量这些发现。
- 原文讨论了测试阶段关于死亡和新发自杀意念的一些警示信号及其他监管问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The authors conducted a systematic review and meta-analysis of the available data on its efficacy against depression and suicidality as well as its side effects. METHODS: MEDLINE was searched with the keyword "esketamine" on March 24, 2024, using the PRISMA method. Data processing and statistical analysis were performed with R, version 4.3.3, and the meta-analysis was performed with the METAFOR package. RESULTS: Of 1,115 articles initially identified, 87 were included for analysis and discussion. At weeks 2-4, randomized controlled trials were mostly negative or failed; however, the meta-analysis returned a weak but significant positive effect for depression (effect size range, 0.15-0.23 at weeks 2-4), similar to augmentation strategies with atypical antipsychotics for treatment-resistant depression. The effect size concerning suicidality was not significant at any time point. The sensitivity analysis produced the same results. CONCLUSIONS: The study findings suggest that esketamine's efficacy as an add-on to antidepressants is modest in treatment-resistant depression (similar to augmentation strategies with atypical antipsychotics) and is absent against suicidality itself. These findings need to be considered in light of esketamine's abuse potential and the fact that long-term effects are still not fully known. Some alarming signs concerning deaths and emerging suicidality during the testing phase are discussed, along with other regulatory issues.
引用
- Fountoulakis KN, Saitis A, Schatzberg AF, et al. Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. Am J Psychiatry. 2025. PMID: 39876682. doi:10.1176/appi.ajp.20240515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。